Nanoparticles for co-delivery of Osimertinib and Selumetinib to Overcome Osimertinib-acquired Resistance in Non-small Cell Lung Cancer.
Sign Up to like & getrecommendations! Published in 2021 at "Acta biomaterialia"
DOI: 10.1016/j.actbio.2021.05.018
Abstract: Osimertinib (OSI) is the first FDA-approved third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI). It can be used for treating non-small cell lung cancer (NSCLC) patients with activating EGFR mutation and for patients… read more here.
Keywords: nsclc; acquired resistance; resistance; osimertinib ... See more keywords
Current perspective: Osimertinib-induced QT prolongation: new drugs with new side-effects need careful patient monitoring.
Sign Up to like & getrecommendations! Published in 2018 at "European journal of cancer"
DOI: 10.1016/j.ejca.2017.12.011
Abstract: An increasing number of tyrosine kinase inhibitors (TKIs) are available for the treatment of non-small cell lung cancer (NSCLC). QT prolongation is one of the known, but relatively rare, adverse events of several TKIs (e.g.… read more here.
Keywords: treatment; monitoring; osimertinib; cancer ... See more keywords
P3.01-29 St.Iv Lung Adenocarcinoma Treated by First-Line EGFR–Tyrosine Kinase Inhibitors-Survival, EGFR Mutation, Histologic Subtype
Sign Up to like & getrecommendations! Published in 2018 at "Journal of Thoracic Oncology"
DOI: 10.1016/j.jtho.2018.08.1589
Abstract: selected variants of the H1650 and H1975 cell lines for resistance to osimertinib to create models in which mechanisms of resistance can be characterized and tested for potential methods to overcome that resistance. Method: Cells… read more here.
Keywords: cell lines; resistance; osimertinib; resistant cell ... See more keywords
Effects of secondary EGFR mutations on resistance against upfront osimertinib in cells with EGFR-activating mutations in vitro.
Sign Up to like & getrecommendations! Published in 2018 at "Lung cancer"
DOI: 10.1016/j.lungcan.2018.10.026
Abstract: OBJECTIVES Non-small cell lung cancers (NSCLCs) that harbor activating mutations for epidermal growth factor receptor (EGFR) show remarkable initial response to EGFR-tyrosine kinase inhibitors (TKIs), but inevitably acquire resistance, half of which are due to… read more here.
Keywords: egfr mutations; egfr tkis; resistance; activating mutations ... See more keywords
Successful treatment with afatinib following the failure of osimertinib rechallenge with osimertinib-induced interstitial lung disease: A case report
Sign Up to like & getrecommendations! Published in 2021 at "Respiratory Medicine Case Reports"
DOI: 10.1016/j.rmcr.2021.101450
Abstract: Herein, we report the case of an 84-year-old woman with epidermal growth factor receptor (EGFR) mutation exon 19 deletion postoperative recurrent lung adenocarcinoma. Osimertinib was administered as a first-line treatment; however, she was urgently admitted… read more here.
Keywords: treatment; disease; case; osimertinib induced ... See more keywords
Effective treatment of pulmonary adenocarcinoma harboring triple EGFR mutations of L858R, T790M, cis-G796s/cis-C797s by osimertinib, brigatinib, and bevacizumab combination therapy: A case report
Sign Up to like & getrecommendations! Published in 2022 at "Respiratory Medicine Case Reports"
DOI: 10.1016/j.rmcr.2022.101582
Abstract: Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) were widely used in advanced non-small cell lung cancers (NSCLCs) with EGFR sensitive mutation and greatly improved the patient survival. With the widespread use of EGFR… read more here.
Keywords: cis c797s; combination; cis; therapy ... See more keywords
[Pulmonary manifestations induced by osimertinib].
Sign Up to like & getrecommendations! Published in 2021 at "Revue des maladies respiratoires"
DOI: 10.1016/j.rmr.2021.12.002
Abstract: INTRODUCTION The third-generation tyrosine kinase inhibitor (TKI) osimertinib is recommended as a first-line treatment in advanced non-small cell lung cancer harboring an activating mutation of Epidermal Growth Factor Receptor (EGFR). Adverse pulmonary events related to… read more here.
Keywords: induced osimertinib; lung; pulmonary manifestations; manifestations induced ... See more keywords
Efficacy and safety of osimertinib for patients with EGFR-mutated NSCLC: a systematic review and meta-analysis of randomized controlled studies
Sign Up to like & getrecommendations! Published in 2022 at "Acta Oncologica"
DOI: 10.1080/0284186x.2022.2132116
Abstract: Abstract Background Osimertinib is a recently approved third-generation epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) that selectively inhibits both EGFR-TKI-sensitizing and EGFR-T790M resistance mutations. The aim of the present meta-analysis was to investigate the… read more here.
Keywords: meta analysis; osimertinib; safety osimertinib; patients egfr ... See more keywords
Successful salvage therapy using high-dose furmonertinib (AST2818) for non–small-cell lung cancer after Osimertinib resistance: a case report
Sign Up to like & getrecommendations! Published in 2022 at "Anti-Cancer Drugs"
DOI: 10.1097/cad.0000000000001368
Abstract: Osimertinib, the third generation of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors, responds well to advanced non–small-cell lung cancer (NSCLC) with the EGFR T790M mutation. However, resistance to osimertinib would inevitably occur. We report… read more here.
Keywords: osimertinib; report; resistance; high dose ... See more keywords
Successful administration of low-dose almonertinib in a patient with lung adenocarcinoma after osimertinib-induced interstitial lung disease: a case report and literature review
Sign Up to like & getrecommendations! Published in 2022 at "Anti-Cancer Drugs"
DOI: 10.1097/cad.0000000000001436
Abstract: Osimertinib, the third generation epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI), is the standard treatment for nonsmall cell lung cancer with EGFR mutation. However, osimertinib-induced interstitial lung disease (OsiILD) is considered to be a… read more here.
Keywords: dose almonertinib; osimertinib; lung; report ... See more keywords
Effective retreatment with osimertinib in CNS-relapsed epidermal growth factor receptor-mutant non-small cell lung cancer patient following resection and adjuvant osimertinib.
Sign Up to like & getrecommendations! Published in 2023 at "Anti-cancer drugs"
DOI: 10.1097/cad.0000000000001521
Abstract: For years, adjuvant chemotherapy has been the only standard treatment for resected non-small cell lung cancer patients (NSCLC), offering a dismal survival improvement at 5 years. Following the outstanding results of the recent ADAURA trial,… read more here.
Keywords: non small; osimertinib; disease; small cell ... See more keywords